María Natalia Gandur Quiroga on JAVELIN Renal 101 trial by Camillo Porta
María Natalia Gandur Quiroga shared on X/Twitter:
”In It for the Long Run: Updated Outcomes From Phase III Trials by Camillo Porta.
JAVELIN Renal 101: Avelumab + axitinib vs sunitinib for aRCC.
- OS: HR 0.88, moderate certainty.
- PFS: HR 0.66, high certainty.
- Grade ≥3 TRAEs: RR 1.09, low certainty.
CheckMate 901 Analysis:
- CR: 16.8% overall; higher in NIVO + CG group.
- LN-only mUC: Better ORR and CR with NIVO + CG vs GC alone.
- OS and PFS: Significantly longer with NIVO + CG.
Key question: Would you use a treatment that didn’t improve OS over alternatives that did?
Elephant in the room: EV-302 trial results impacting CheckMate 901 outcomes.
EV+P in LN-only aUC:
- ORR: 77.5% (EV+P) vs 53.4% (Chemotherapy).
- mOS: Not reached (EV+P) vs 27.5 months (Chemotherapy).
Subanalysis of CN901:
- LN-only disease: Favorable prognostic factor, possible standard of care with NIVO + CG.”
Source: María Natalia Gandur Quiroga/X
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
